A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.
Reuters reported that the ruling reinforces a jury's finding that Lilly knowingly misreported drug prices, depriving the government of millions in rebates.
